Skip to main content
Premium Trial:

Request an Annual Quote

Avant Completes Acquisitions of Amarantus, Theranostics Health

NEW YORK (GenomeWeb) – Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health.

In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus' research-use-only assays for multiple sclerosis and Alzheimer's disease with Avant's upcoming microarray-based ovarian cancer diagnostic OvaDx.

Under the terms of that arrangement, Avant acquired all outstanding shares of Amarantus in exchange for 80 million shares of Avant stock, with additional shares to be issued upon certain undisclosed milestones.

Two months later, Avant and Amarantus announced that they had signed a letter of intent to add privately held Theranostics to the merger, which would give the combined company a CLIA lab to support its pipeline of diagnostics, as well as Theranostics' TheraLink assay for identifying known drug targets of breast cancer therapeutics.

Under the terms of the deal, Avant acquired the assets and operations of Theranostics in exchange for 25 million shares of its stock, which was trading at $.32 per share on the OTC Bulletin Board on Thursday morning.

The stock issued under the two transactions are subject to an 18-month lockup, with certain exceptions.

"The closing of these acquisitions marks a pivotal moment for Avant," Avant President and CEO Gregg Linn said in a statement. "We have simultaneously expanded our product pipeline … [and] have acquired the appropriate CLIA/CAP infrastructure required to commercialize our pipeline while also gaining access to a growing pharma services revenue stream with the very same sales, distribution channels, commercial relationships, and overall scientific focus required for successful introduction of our additional proprietary assets to the pharma services market."

The Scan

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on additional RNA-seq data from human and mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.